Insider’s View: Deciphering Ironwood Pharmaceuticals Inc (IRWD)’s Financial Health Through Ratios

Abby Carey

Beyond market trends, investors keen on maximizing returns delve into the world of stock picking. The right selections can be instrumental in catapulting your wealth.

The price of Ironwood Pharmaceuticals Inc (NASDAQ: IRWD) closed at $3.69 in the last session, up 2.22% from day before closing price of $3.61. In other words, the price has increased by $2.22 from its previous closing price. On the day, 2.52 million shares were traded. IRWD stock price reached its highest trading level at $3.85 during the session, while it also had its lowest trading level at $3.5935.

Ratios:

We take a closer look at IRWD’s different ratios to gain a better understanding of the stock. It provided that stocks Price–to–Cash (P/C) ratio for the trailing twelve months (TTM) is standing at 4.28 whereas its Price-to-Free Cash Flow (P/FCF) for the term is 8.87. For the most recent quarter (mrq), Quick Ratio is recorded 1.13 and its Current Ratio is at 1.13.

Insider Transactions:

An investor can also benefit from insider trades by learning what management is thinking about the future direction of stock prices. A recent insider transaction in this stock occurred on Nov 17 ’25 when Gaskins Tammi L sold 6,016 shares for $3.32 per share. The transaction valued at 19,973 led to the insider holds 235,264 shares of the business.

Gaskins Tammi L bought 6,324 shares of IRWD for $21,312 on Nov 17 ’25. On Aug 11 ’25, another insider, Gaskins Tammi L, who serves as the Chief Commercial Officer of the company, sold 1,316 shares for $0.84 each. As a result, the insider received 1,105 and left with 241,280 shares of the company.

Valuation Measures:

Investors should consider key stock statistics when deciding whether to invest or divest. In the wake of the recent closing price, IRWD now has a Market Capitalization of 600284160 and an Enterprise Value of 1058117184. As of this moment, Ironwood’s Price-to-Earnings (P/E) ratio for their current fiscal year is 23.90, and their Forward P/E ratio for the next fiscal year is 8.25. For the stock, the TTM Price-to-Sale (P/S) ratio is 1.77. Its current Enterprise Value per Revenue stands at 3.121 whereas that against EBITDA is 7.263.

Stock Price History:

The Beta on a monthly basis for IRWD is 0.18, which has changed by 0.014045 over the last 52 weeks, in comparison to a change of 0.13042927 over the same period for the S&P500. Over the past 52 weeks, IRWD has reached a high of $5.13, while it has fallen to a 52-week low of $0.53. The 50-Day Moving Average of the stock is 54.74%, while the 200-Day Moving Average is calculated to be 172.99%.

Shares Statistics:

According to the various share statistics, IRWD traded on average about 2.11M shares per day over the past 3-months and 2247270 shares per day over the past 10 days. A total of 162.68M shares are outstanding, with a floating share count of 156.69M. Insiders hold about 3.68% of the company’s shares, while institutions hold 91.66% stake in the company. Shares short for IRWD as of 1764288000 were 7464531 with a Short Ratio of 3.54, compared to 1761868800 on 4762545. Therefore, it implies a Short% of Shares Outstanding of 7464531 and a Short% of Float of 6.950000000000001.

Earnings Estimates

At present, 2.0 analysts are actively evaluating the performance of Ironwood Pharmaceuticals Inc (IRWD) in the stock market.The consensus estimate for the next quarter is $0.02, with high estimates of $0.08 and low estimates of -$0.04.

Analysts are recommending an EPS of between $0.32 and $0.27 for the fiscal current year, implying an average EPS of $0.29. EPS for the following year is $0.46, with 3.0 analysts recommending between $0.5 and $0.41.

Revenue Estimates

According to 3 analysts,. The current quarter’s revenue is expected to be $58.43M. It ranges from a high estimate of $60.6M to a low estimate of $57M. As of. The current estimate, Ironwood Pharmaceuticals Inc’s year-ago sales were $90.55MFor the next quarter, 3 analysts are estimating revenue of $38.2M. There is a high estimate of $38.2M for the next quarter, whereas the lowest estimate is $38.2M.

A total of 3 analysts have provided revenue estimates for IRWD’s current fiscal year. The highest revenue estimate was $309.1M, while the lowest revenue estimate was $305.6M, resulting in an average revenue estimate of $306.97M. In the same quarter a year ago, actual revenue was $351.41MBased on 3 analysts’ estimates, the company’s revenue will be $319.47M in the next fiscal year. The high estimate is $334.2M and the low estimate is $310.2M.

DwinneX
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.